Head and Neck Cancer

P=N/A, N=1470, Recruiting, Peter MacCallum Cancer Centre | Not yet recruiting --> Recruiting

P=N/A, N=60, Completed, Peter MacCallum Cancer Centre | Recruiting --> Completed

Depletion of LINC02154 suppressed expression of mitochondrial genes, including MTCO1 and MTCO2, and inhibited mitochondrial respiratory function in OSCC cells. These results suggest that LINC02154 exerts its oncogenic effects by modulating the cell cycle and oxidative phosphorylation in OSCC, highlighting LINC02154 as a potential therapeutic target.

ST from LSCC showed that spots with high-risk scores were colocalized with TGF-β and the proliferating malignant cells, additionally, the risk scores have a negative correlation with TCR signaling but positive association with LAG3 transcription. The CDRscore model could be utilized as a powerful prognostic indicator for HNC.

A combined score derived from TPS and ISS optimized recurrence prediction and stratified survival in a manner generalizable to three external cohorts. We provide novel evidence that limiting genomic instability makes tumor-intrinsic and immune-mediated contributions to HPV+ OPSCC recurrence risk, opening opportunities to detect and target this treatment-resistant biology.

Subsequently, we performed in vitro studies by HNSCC-PDO and SCC-9 and found that CES1-overexpressing cells exhibited reduced sensitivity to cisplatin and stronger tumor malignant biological behavior compared with CES1-knockdown cells. The observed association between CES1 expression and tobacco smoking implies a potential influence of smoking on the efficacy of cisplatin-based chemotherapy in HNSCC through the regulation of CES1 expression.

P1/2, N=288, Recruiting, BicycleTx Limited | Trial completion date: Oct 2026 --> Oct 2025

P=N/A, N=107, Completed, Helsinki University Central Hospital

P=N/A, N=200, Recruiting, The First Affiliated Hospital with Nanjing Medical University

P1/2, N=48, Active, not recruiting, National University Hospital, Singapore | Not yet recruiting --> Active, not recruiting | Trial completion date: Mar 2024 --> Jun 2025 | Trial primary completion date: Mar 2023 --> Jul 2024

Moreover, the schwannoma/meningioma-derived NF2 LOF mutations not only inhibit its tumor suppressive function in the Hippo pathway, but also gain an oncogenic role for NF2 by activating the VANGL-JNK pathway. Collectively, our study not only offers a rich somatic mutation resource for investigating the Hippo pathway in human cancers, but also provides a molecular basis for Hippo-based cancer therapy.

ELF3 silencing reduced viability, induced cell cycle arrest and suppressed expressions of CCNE2, E6 and E7 in HPV16 E6/E7-expressing HFKs. Downregulation of ELF3 played an inhibiting role in the malignant transformation of HPV16 E6/E7-immortalized HFKs by decreasing CCNE2 expression.

P1/2, N=26, Active, not recruiting, Viracta Therapeutics, Inc. | N=130 --> 26

P=N/A, N=160, Active, not recruiting, Erasmus Medical Center

P2, N=45, Not yet recruiting, The First Affiliated Hospital with Nanjing Medical University

P=N/A, N=40, Recruiting, National Taiwan University Hospital | Not yet recruiting --> Recruiting

P3, N=408, Not yet recruiting, Rakuten Medical, Inc.

P1, N=12, Not yet recruiting, Pure Biologics S.A.

P=N/A, N=30, Completed, Mahidol University | Enrolling by invitation --> Completed | N=88 --> 30 | Trial completion date: Sep 2023 --> Jun 2024

Our study highlights the critical need for blocking both intrinsic and extrinsic mechanisms of resistance for the prolonged response and shows that such treatment is ineffective in KRASG12Ci-AcR tumors.

Pulrodemstat is an effective therapeutic drug for HNSCC. Thus, the TET3/KDM1A axis may account for the malignant phenotype of HNSCC.

Furthermore, OV combined with TIL adoptive therapy can endow tumor cells with aAPC characteristics, activate T cells at the same time, and reprogram tumor macrophages into anti-tumor phenotype. OV-4-1BBL/IL15 can stimulate the anti-tumor potential of TIL therapy in HCC, and possess broad clinical application prospects.

Overall, MLN4924 disrupted Neddylation pathway and stabilized TSC2, thereby inactivating the mTOR pathway. The study provided a theoretical basis for the clinical potential of MLN4924 in improving treatment outcomes for HNSCC patients, offering a novel strategy for addressing this challenging disease.

According to the findings of the present study, systemic inflammatory markers may help predict the prognosis, activation, and exhaustion of circulating T cells. In patients with R/M head and neck cancer treated with nivolumab, systemic inflammatory markers could provide new insights into rational strategies in cancer immunotherapy for R/M head and neck cancer.

For several head and neck SCC, measurement of CD8+ TILs in the central or intratumoral compartment, followed by the stromal compartment, has been most consistently associated with survival. Future studies are needed to evaluate subpopulations of CD8+ TILs and biomarker-based treatment selection.

Dendritic cell populations were identified as high-scoring cell populations, and the pathways of interaction between this cell population and other cell populations were explored. We identified E2F1 as an independent prognostic factor closely associated with the prognosis and immune response of HNSCC.

Our study suggests epigenetic mechanisms, particularly via EZH2, play a crucial role in SNUC carcinogenesis. Furthermore, distinctive immune cell profiles in SNUC point to potential immune-related characteristics of this malignancy.

Loco-regional treatments may also play a key role in the management of metastatic HPV OPSCC depending on the pattern of presentation. Our case series highlights all these novelties that could lead to better treatment outcomes.

P=N/A, N=86, Recruiting, University of Alcala | Trial primary completion date: Sep 2024 --> Dec 2024

P2, N=120, Recruiting, Matrix Biomed, Inc. | Trial completion date: Apr 2023 --> Dec 2025 | Trial primary completion date: Jan 2023 --> Jul 2025

P2, N=96, Completed, Washington University School of Medicine | Active, not recruiting --> Completed | Trial completion date: Dec 2024 --> Jul 2024

P2, N=98, Not yet recruiting, NRG Oncology | Trial completion date: Sep 2026 --> Jan 2027 | Initiation date: Oct 2024 --> Apr 2025 | Trial primary completion date: Sep 2026 --> Jan 2027

P1, N=24, Not yet recruiting, MegaPro Biomedical Co. Ltd. | Trial completion date: May 2025 --> Dec 2025 | Initiation date: Sep 2024 --> Dec 2024 | Trial primary completion date: Feb 2025 --> Oct 2025

P1/2, N=25, Recruiting, Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau | Not yet recruiting --> Recruiting

P=N/A, N=20, Completed, University of Alcala | Active, not recruiting --> Completed

P1/2, N=217, Recruiting, Janssen Research & Development, LLC | N=117 --> 217

Furthermore, this combination shows a cooperative anti-tumor activity with anti-PD-1 in treating head and neck tumors. Overall, these findings highlight a Th response and macrophage phenotype reprograming involved functional mechanism underlying the cooperative activity of the combination of TLR9 and STING agonists in the immunotherapy of head and neck cancer.

We have developed an SMPD, cyclooxygenase-2 (COX-2) targeting pH-activable fluorophore named CNP, combining a potent COX-2 inhibitor, celecoxib, linked to a naphthalimide fluorophore with an acidic microenvironment-responsive piperazine moiety for specific optical imaging of OSCC in cells and patient tissues...Further, CNP is demonstrated in imaging OSCC cells in patient-derived biopsies. Thus, multifunctional CNP shows potential in exploring more reagents for fluorescence-based detection of OSCC cells in patient tissues with translational applications.

Highly accurate histologic subtyping of salivary gland carcinomas can be performed by preoperative CNB; however, specificity can be more challenging in pathologically heterogenous tumors.

Although SNPs in CYP1A1, COX2, SOD2, and HIF1α were not significantly associated with OC risk in the Pakistani population, altered protein expression levels of COX2, HIF1α and SOD2 suggest additional regulatory mechanisms. Further investigation into post-transcriptional modifications and epigenetic factors could lead to novel biomarkers and therapeutic targets for OC in Pakistan.

Significant interactions between TMB and peripheral immune profiles for both progression-free and overall survival were found. Clinically relevant pretreatment peripheral immune biomarkers were identified, demonstrating the potential of DNA-based immune profiling to predict ICI response before treatment.

Mechanistically, IL-12 is essential for the expression of NKG2A on CD8 T cells in a CD40/CD40L- dependent manner, in conjunction with TCR stimulation. Our study thus reveals that NKG2A is induced by IL-12 on human tumor-reactive CD8 T cells exposed to a TGF-β-rich environment, highlighting an underappreciated immuno-regulatory feedback loop dependent on IL-12 stimulation.